证券代码：600750 证券简称：江中药业 公告编号：2025-054 江中药业股份有限公司 第十届监事会第八次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 报告内容详见上海证券交易所网站（www.sse.com.cn）。 二、关于公司 2021 年限制性股票激励计划首次授予部分第三个解锁期解 锁条件成就的议案 表决情况：3 票同意，0 票反对，0 票弃权，通过本议案。 监事会认为，鉴于激励计划首次授予部分限制性股票第三个解除限售期解 除限售条件已经成就，同意公司为符合解除限售条件的 70 名激励对象办理限制 性股票解除限售相关事宜，解除限售数量合计为 1,392,949 股。该等事项符合 《上市公司股权激励管理办法》等法律法规、规范性文件及《江中药业 2021 年 限制性股票激励计划（2022 年 11 月修订稿）》《公司章程》的有关规定，不存 在损害公司及股东利益的情况。 具体内容详见公司《江中药业关于 2021 年限制性股票激励计划首次授予部 1 / 2 江中药业股份有限公司（以下简称"公司"）第十 ...

关于公司 2021 年限制性股票激励计划首次授予部分第三个 解锁期解锁条件成就的核查意见 江中药业股份有限公司监事会 2025 年 10 月 24 日 根据《上海证券交易所股票上市规则》和《上市公司股权激励管理办法》等 相关法律、法规以及《江中药业 2021 年限制性股票激励计划（2022 年 11 月修 订稿）》的有关规定，江中药业股份有限公司监事会审阅了《关于公司 2021 年 限制性股票激励计划首次授予部分第三个解锁期解锁条件成就的议案》,并提出 如下书面审核意见： 江中药业股份有限公司监事会 监事会认为：鉴于本激励计划首次授予限制性股票第三个解除限售期的相关 解除限售条件已成就，公司董事会根据 2021 年第二次临时股东大会的授权，按 照本激励计划的相关规定为符合条件的 70 名激励对象办理本激励计划首次授予 限制性股票第三次解除限售的相关事宜，该等事项符合《上市公司股权激励管理 办法》等法律法规、规范性文件及《激励计划》《公司章程》的有关规定，不存 在损害公司及股东利益的情况。 ...

董事会认为，《江中药业 2025 年第三季度报告》真实反映了公司 2025 年前 三季度的财务状况和经营成果，编制程序符合相关法律法规、中国证券监督管 理委员会和上海证券交易所的相关规定，报告内容真实、准确、完整，不存在 虚假记载、误导性陈述或重大遗漏。 证券代码：600750 证券简称：江中药业 公告编号：2025-053 江中药业股份有限公司 第十届董事会第九次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 江中药业股份有限公司（以下简称"公司"或"江中药业"）第十届董事会 第九次会议于 2025 年 10 月 24 日在公司会议室以现场结合视频方式召开，会议 通知于 2025 年 10 月 17 日以书面形式发出，会议应到董事 9 人，实到董事 9 人。 公司监事和高级管理人员列席。本次会议召集召开符合《公司法》和《公司章 程》的有关规定。 会议由公司董事长刘为权先生主持，经与会董事充分研究和讨论，审议通 过以下议案： 一、公司 2025 年第三季度报告 表决情况：9 票同意，0 票反对，0 票弃权， ...

Core Viewpoint - China Resources Pharmaceutical (03320) reported a decline in total revenue for Jiangzhong Pharmaceutical for the nine months ending September 30, 2025, while net profit showed an increase [1] Financial Performance - Total revenue reached 2.933 billion RMB, representing a year-on-year decrease of 6.28% [1] - Net profit amounted to 743 million RMB, reflecting a year-on-year increase of 6.02% [1]

Financial Performance - The company's operating revenue for Q3 2025 was approximately ¥792.05 million, a decrease of 7.59% compared to the same period last year[5]. - The total profit for the period reached approximately ¥220.45 million, reflecting a 12.59% increase year-on-year[5]. - Net profit attributable to shareholders was approximately ¥161.11 million, up 4.70% from the previous year[5]. - Total operating revenue for the first three quarters of 2025 was CNY 2,933,172,225.19, a decrease of 6.3% compared to CNY 3,129,708,148.79 in the same period of 2024[26]. - Net profit for the first three quarters of 2025 reached CNY 742,687,211.39, an increase of 6.0% from CNY 700,545,782.06 in 2024[27]. - Operating profit for the first three quarters of 2025 was CNY 918,410,081.64, up 11.6% from CNY 822,775,990.62 in 2024[26]. - The company reported a basic earnings per share of CNY 1.08 for the first three quarters of 2025, compared to CNY 1.03 in the same period of 2024[27]. Cash Flow and Liquidity - The net cash flow from operating activities for the year-to-date period was approximately ¥973.77 million, a significant increase of 100.02%[5][14]. - The company’s cash flow from operating activities for the first three quarters of 2025 showed a positive trend, indicating improved liquidity[28]. - In the first three quarters of 2025, the cash inflow from operating activities reached ¥3,743,528,007.08, an increase of 17.1% compared to ¥3,196,192,689.67 in the same period of 2024[29]. - The net cash flow from operating activities was ¥973,774,302.08, significantly up from ¥486,848,317.40 in the previous year, marking a growth of 100%[29]. - The cash inflow from investment activities totaled ¥1,123,730,620.24, compared to ¥1,010,467,119.59 in the first three quarters of 2024, reflecting a rise of 11.2%[30]. - The net increase in cash and cash equivalents for the period was ¥115,014,135.29, contrasting with a decrease of -¥84,583,742.68 in the previous year[30]. - The ending balance of cash and cash equivalents stood at ¥766,938,443.98, up from ¥557,557,153.47 at the end of the third quarter of 2024[30]. Assets and Liabilities - Total assets at the end of the reporting period were approximately ¥6.89 billion, representing a 5.89% increase from the previous year-end[7]. - The company's current assets reached RMB 3.42 billion, up from RMB 2.49 billion at the end of 2024, indicating a significant increase of approximately 37.38%[21]. - The total liabilities of Jiangzhong Pharmaceutical were reported at RMB 3.42 billion, with a notable increase in accounts payable to RMB 178.81 million from RMB 162.75 million[22]. - The total liabilities of the company as of the reporting date were CNY 2,444,005,425.11, an increase from CNY 2,036,298,092.84 in the previous year[23]. - The total equity attributable to shareholders of the parent company was CNY 3,795,544,059.28, slightly down from CNY 3,862,808,649.61 in the previous year[23]. Segment Performance - The gross profit margin for the pharmaceutical industry segment was 66.07%, a slight increase of 0.41 percentage points year-on-year[12]. - Revenue from the non-prescription drug segment was approximately ¥2.09 billion, with a gross margin of 76.34%[12]. - Revenue from the health consumption products segment increased by 35.06% year-on-year, with a gross margin of 40.04%[12]. - The company reported a significant decline in revenue from the South China region, down 15.42% compared to the previous year[13]. Investments and Acquisitions - The company acquired a 51% stake in Jiangxi Jiangzhong Traditional Chinese Medicine Co., Ltd. in December 2024, leading to retrospective adjustments in financial data[7]. - Jiangzhong Pharmaceutical's long-term investments rose to RMB 32.81 million, up from RMB 31.32 million, showing an increase of approximately 4.77%[22]. Shareholder Information - The company has no significant changes in the top ten shareholders, with the largest shareholder holding 273.86 million shares, representing 43.13% of the total shares[18]. - The company completed a share buyback plan, acquiring 2,844,550 shares, which is 0.45% of the total share capital, for a total amount of RMB 61.29 million[19]. Future Outlook - The company plans to continue expanding its market presence and product development initiatives in the upcoming quarters[19]. - The company plans to continue focusing on market expansion and new product development to drive future growth[28]. Research and Development - Research and development expenses increased to CNY 97,139,720.32 in the first three quarters of 2025, up 15.9% from CNY 83,766,279.51 in 2024[26]. Inventory and Receivables - Inventory levels increased to RMB 530.53 million from RMB 460.97 million, marking a rise of approximately 15.06%[21]. - The company reported a decrease in accounts receivable from RMB 440.61 million to RMB 482.16 million, indicating a change of about 9.43%[21]. Accounting Standards - The company did not apply new accounting standards for the first time in 2025[31].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告 全部或任何部份內容而產生或因倚賴該等內容而引致之任何損失承擔任何責 任。 （於香港註冊成立的有限公司） （股份代號：3320） 截至2025年9月30日止九個月的未經審核財務業績 於2025年10月24日，江中藥業公佈其截至2025年9月30日止九個月的季度報 告。 江中藥業股份有限公司（「江中藥業」）為一家於中華人民共和國註冊成立的公 司。江中藥業的股份於上海證券交易所上市。截至本公告日期，江中藥業由華 潤醫藥集團有限公司（「本公司」，連同其附屬公司合稱為「本集團」）非全資附 屬公司華潤江中製藥集團有限責任公司持有約43.14%的權益，本集團實際控 制江中藥業26.12%並以本公司附屬公司的形式入帳。 1 於2025年10月24日，江中藥業公佈其截至2025年9月30日止九個月的季度報告 （「江中藥業未經審核財務資料」）。下表載列江中藥業未經審核財務資料的主 要財務資料： 截至9月30日止九個月 | | 2025年 | 2024年 | | --- | --- | --- ...

江中药业10月24日公告，2025年第三季度实现营业收入7.92亿元，同比下降7.59%；归属于上市公司股 东的净利润1.61亿元，同比增加4.70%；基本每股收益0.26元。 ...

格隆汇10月24日丨江中药业(600750.SH)公布，公司第三季度实现营业收入7.92亿元，同比下降7.59%； 归属于上市公司股东的净利润1.61亿元，同比增长4.70%；归属于上市公司股东的扣除非经常性损益的 净利润1.58亿元，同比增长9.46%；基本每股收益0.26元。 ...

Core Viewpoint - Jiangzhong Pharmaceutical (600750.SH) announced that China Resources Jiangzhong has completed its share buyback plan, acquiring a total of 2.8446 million shares, which represents 0.45% of the company's total share capital, for an amount of 61.2922 million yuan excluding transaction fees [1] Group 1 - The buyback period was from October 22, 2024, to October 21, 2025, during which no trading occurred [1] - As of the announcement date, China Resources Jiangzhong holds 273,916,036 shares, accounting for 43.14% of the total share capital [1] - The buyback plan has been fully implemented within the specified timeframe and complies with relevant requirements [1]

关于控股股东增持股份结果的公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 已披露增持计划情况：江中药业股份有限公司（以下简称"公司"）于 2024 年 10 月 22 日在上海证券交易所网站（www.sse.com.cn）披露了《江中药 业关于控股股东增持公司股份计划的公告》（2024-046），公司控股股东华润江中 制药集团有限责任公司（以下简称"华润江中"）计划自 2024 年 10 月 22 日起 12 个月内，通过上海证券交易所允许的方式（包括但不限于集中竞价交易、大 宗交易等）增持公司 A 股股份，总体增持金额不低于 0.6 亿元人民币（含），不 超过 1.2 亿元人民币（含）。 增持计划的实施结果：2024 年 10 月 22 日至 2025 年 10 月 21 日期间（窗 口期不交易），华润江中通过上海证券交易所证券交易系统累计增持公司股份 2,844,550 股，占公司总股本的 0.45%，增持金额 61,292,218.30 元（不含交易 费用）。截至本公告日，华润江中持有公司 ...